For virologically suppressed adult patients with HIV-1. See Full Indication.

JULUCA | Mechanism of Action Video

Dr. Andrew Zolopa, Head of North America Medical Affairs for ViiV Healthcare, discusses the mechanism of action for JULUCA, a complete, dolutegravir-based, 2-drug regimen for virologically suppressed (HIV-1 RNA <50 copies/mL on a stable antiretroviral therapy for at least 6 months) adult patients with HIV. The video gives a walkthrough of the HIV life cycle and how the pairing of dolutegravir and rilpivirine inhibits the viral life cycle at 2 separate sites, like traditional 3-drug regimens.

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/viiv/julucahcp/10994778-moa.mp4

You may also be interested in

CLINICAL TRIALS

Read more »

RISKS & SIDE EFFECTS

Read more »

PATIENT SUPPORT

Read more »